Design Therapeutics (DSGN) Cash from Operations (2020 - 2021)
Historic Cash from Operations for Design Therapeutics (DSGN) over the last 2 years, with Q4 2021 value amounting to -$9.2 million.
- Design Therapeutics' Cash from Operations fell 22443.74% to -$9.2 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$29.4 million, marking a year-over-year decrease of 23887.41%. This contributed to the annual value of -$43.1 million for FY2024, which is 2639.17% up from last year.
- Latest data reveals that Design Therapeutics reported Cash from Operations of -$9.2 million as of Q4 2021, which was down 22443.74% from -$8.2 million recorded in Q3 2021.
- In the past 5 years, Design Therapeutics' Cash from Operations ranged from a high of -$1.3 million in Q2 2020 and a low of -$9.2 million during Q4 2021